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Abstract
BACKGROUND/PURPOSE: Pain management for hip fracture patients in the time before

surgery is crucial. Literature highlights the success of local, single injection nerve blocks to aid in
preoperative pain management. A local hospital implemented a preoperative, single injection nerve
block protocol in March 2018. This quality improvement project investigated: (1) organization
protocol compliance, and (2) if the preoperative single injection nerve block protocol reduces hip
fracture pain, use of systemic opioid analgesics, decreases incidence of adverse opioid effects, and
reduces cost of care. SUBJECTS: Patients ages 18 and older admitted with the primary diagnosis
of an operable isolated hip fracture (n=100). METHODS: Data measures were extracted from the
electronic health records and the trauma registry and were entered into REDCap encrypted
software. ANALYSIS: Data was analyzed using SAS statistical software to verify whether the
intervention was successful in meeting cost, quality, and compliance measures. RESULTS:
Results were not statistically significant in reducing oral and intravenous narcotic use before
(p=0.80; p=0.39) and after (p=0.23; p=0.10) surgical correction, nor was there statistically
significant change in adverse effects (p=0.10) and length of stay (p=0.90). However, there was a
statistically significant reduction in preoperative pain levels following nerve block administration
(p<0.0001).Protocol compliance was 66% over seven months. CONCLUSION: The results of this
project were consistent with the literature; nerve block injection may reduce preoperative pain for
patients with an operable hip fracture. Further investigation is needed to determine if narcotic use
and length of stay could be impacted if time variability in nerve block administration were reduced
and if protocol compliance were increased.
Keywords: hip fractures, preoperative period, nerve block, and pain management
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FINAL DEFENSE
An Evaluation of a Nerve Block Protocol in Hip Fracture Patients
Introduction
Hip fractures are a debilitating injury associated with acute pain, functional impairment,

increased morbidity and mortality, and substantial financial burden (Centers for Disease Control
and Prevention [CDC], 2016a; Riddell, Ospina, & Holroyd-Leduc, 2016; Sanzone, 2016). For
those ages 65 and older, this type of injury is one of the most common reasons for admission to an
orthopedic unit, resulting in over 300,000 hospitalizations annually (CDC, 2016a; Freeman &
Clarke, 2016; HCUPnet, 2012). One of the most important aspects of surgery is pain management,
as most hip fracture patients experience moderate to severe pain (Sanzone, 2016). Effective pain
control is associated with early postoperative ambulation and functional recovery, decreased length
of stay, decreased thrombotic events, and improved patient satisfaction (Wang, Sun, Wang, Hao,
2017).
Yet, optimal pain control is typically underutilized in hip fracture care (Haslam, Lansdown,
Lee, van der Vyver, 2013). There is limited research and expert agreement on the most effective
approach to controlling preoperative hip fracture pain. The current standards of practice reflect an
opioid model of analgesia. However, systemic opioid use in the preoperative phase is associated
with significant side effects, such as nausea, vomiting, constipation, confusion or delirium,
drowsiness, and respiratory depression (Freeman & Clarke, 2016; Sanzone, 2016; Wang et al.,
2017).
Additionally, mismanaged preoperative pain is associated with increased cost of care,
prolonged rehabilitation, patient dissatisfaction, and overall increased risk of morbidity and
mortality (Riddell et al., 2016; Sanzone, 2016). Therefore, early effective preoperative pain
management represents a key opportunity for patient care improvement.
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An abundance of literature supports the use of nerve blocks as an effective adjunct for
localized, preoperative pain control (Morrison, et al., 2016; Sanzone, 2016; Riddell et al., 2016;

Ritcey, Pageau, Woo, & Perry, 2016). A nerve block is an injection of a local anesthetic around a
nerve. In the case of a hip fracture, the injection would be localized to one of the branches of the
lumbar plexus. The nerve block relieves pain regionally by interrupting pain signal transmission to
the central nervous system (Wang et al., 2017). Common orthopaedic nerve blocks include a psoas
compartment block, a femoral block, fascia iliaca compartment block, or combined nerve blocks.
The techniques of administering a local nerve block include the landmark method, a nerve
stimulator, or an ultrasound (Guay, Parker, Griffiths, & Kopp, 2017). These nerve blocks then
target pain locally, which reduces systemic side effects of traditional narcotic use. Side effects may
include injection site hematoma, nerve damage, block failure, and local anesthetic toxicity.
The orthopedic physicians at XXX decided to implement a standardized protocol where all
individuals admitted with a primary diagnosis of an isolated hip fracture would receive a
preoperative localized, single injection nerve block. This standardized protocol was developed by
the orthopaedic clinical nurse specialist (CNS) in December of 2017. It was enacted officially in
March 2018 to improve hip fracture pain management from the point of emergency department
admission to the operating room. The purpose of this quality improvement is therefore to
determine whether or not the nerve block protocol will reduce preoperative pain, narcotic
medication use, narcotic-related adverse effects, and inpatient care cost in operable hip fractures.
Assessment of the Organizational
Framework for Assessment
The Burke-Litwin Model of Organizational Performance and Change (1992) is a causal
model describing the twelve interconnected factors of organizational change (see Appendix A). The
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Burke-Litwin Model (1992) is divided into microscopic, or transactional factors, and macroscopic,
or transformational factors. Microscopic, or transactional, variables include work unit climate,
management practices, structure, task and individual skills, motivation, systems, individual needs
and values, and individual and organizational performance (Burke & Litwin, 1992). Macroscopic,
or transformational, variables include external environment, leadership, mission and strategy, and
organizational culture (Burke & Litwin, 1992). This model has content validity and internal
reliability, which means that it consistently measures what it purports to measure across all of its
constructs (Burke & Litwin, 1992; Stone, 2015).
Ethics and Protection of Human Subjects
Prior to data collection and analysis, an application was submitted to the XXX Institutional
Review Board. No project activites will commence prior to review and approval by the Board. The
purpose and scope of this project was limited to evidence-based quality improvement. The data
used for analysis was de-identified and coded when pulled from the patient chart and transferred to
a data collection tool. No research consent was needed for this quality improvement project, as it
entails retrospective data collection. All members of the team have completed human subjects
protection training via the Collaborative Institute Training Initiative and their interactions with
patient records were guided accordingly.
Stakeholders
Key stakeholders include those individuals or groups entrenched and invested in the
organization (Moran et al., 2017). Consulting with people that have skill sets, experience, and
perspectives provide valuable insight to the organization practices. Within the context of this
project, the key stakeholders include the healthcare providers and residents (orthopeadics,
emergency medicine, internal medicine, and anesthesia), nurse practitioners, physician assistants,
the rapid response team, patients, registered nurses (RNs), unit leadership (ED, PACU, OR, and
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OU managers), and each unit’s clinical nurse specialists (CNSs) and leaders (CNLs). The
orthopaedic physicians and residents order pain medications before and after surgery and perform
the surgeries. RNs administer the pain medications, assess and monitor the patient response, and
document pain scores before, during, and after surgery. This helps ensure accurate and timely
documentation of pain treatment. Patients receive the pain medication as well as undergo surgery
for their hip fractures. Unit leadership and the CNSs monitor unit processes, satisfaction, and
compliance with organization policy, quality, and standards. Therefore, all are considered key
stakeholders in this organizational assessment.
SWOT
A SWOT analysis is a tool used to evaluate the current state of an organization. The
acronym SWOT stands for ‘strengths’, ‘weaknesses’, ‘opportunities’, and ‘threats’ (Gurel & Tat,
2017). Threats refer to situations or entities that may endanger or impede the organization’s
functions. Opportunities refer to situations, resources, or entities that an organization may use
advantageously and/or to counteract threats (Gurel & Tat, 2017). Internal strengths include
advantageous and unique characteristics that differentiate the organization from its competitors. A
weakness, though, refers to an organization’s lack of situations, resources, functions, or abilities,
which contribute to inefficient or ineffective functioning (Gurel & Tat, 2017).
This analysis assessed an organization’s external threats and opportunities as well as its
internal strengths and weaknesses. A SWOT analysis was conducted to assess the current state of
hip fracture pain control across the ED, PACU, OR and OU (see Appendix B). The awareness
gleaned from this analysis can help the organization reach preoperative hip fracture pain
management goals (Gurel & Tat, 2017).
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Strengths of the organization include leadership training in Lean Six Sigma, a culture of
process improvement, organization-wide teamwork, Magnet designation, The Joint Commission
(TJC) orthopaedic certifications, Hospital Quality Awards, Clinical Quality Awards for joint
replacements, the presence of an orthopaedic nurse navigator, and joint repair preparation classes
(American Nurses Association, American Nurses Credentialing Center, & American Nurses
Foundation, 2018; GoLeanSixSigma, 2016; Healthgrades, 2018; TJC, 2018). Major weaknesses of
the organization are a lack of standardized pain management for hip fractures and use of variable
orthopaedic order sets for patients. Other weaknesses include an inability for providers to regularly
meet face to face, anesthesiology staffing, new provider unfamiliarity, transitions of care at
discharge, and utilizing the same diagnostic related group (DRG) codes for hip fractures and
elective hip arthroplasty.
Opportunities for the organization include decreasing the unnecessary use of opioids,
implementing new evidence in the form of preoperative nerve blocks, and the new orthopaedic
group merger (Morrison, et al., 2016; Sanzone, 2016; Riddell et al., 2016; Ritcey, Pageau, Woo, &
Perry, 2016). Additionally, another opportunity includes gleaning insight from sister organizations
with similar protocols. Threats to the organization are competition from other local hospitals with
already established nerve block protocols, local branding from other hospitals, insurance company
preference, and Centers for Medicaid and Medicare reimbursement measures (CMS, 2018).
Clinical Practice Question
The organizational assessment and SWOT analysis suggest that the already implemented
nerve block protocol can positively impact hip fracture care. The clinical practice questions are: (1)
Does this preoperative, single-injection nerve block, which serves as a pain management adjunct,
reduce preoperative reports of pain, overall administration frequency of opioid analgesic/morphine
equivalents, incidence of opioid-associated adverse effects, and costs of inpatient care in hip
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fracture patients over an 8 month period compared to standard preoperative opioid analgesic
therapy/morphine equivalents? (2) What is the protocol compliance rate?
Review of the Literature
Method
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)

guideline served as the framework for this review (Moher, Liberati, Tetzlaff, Altman, & PRISMA
Group, 2009). A comprehensive search was conducted in the PubMed, Cochrane Library,
CINAHL, and Web of Science databases and was limited to reviews in the English language from
2008 to 2018. Keywords were hip fractures, preoperative period, nerve block, and pain
management. The search expertise of an experienced librarian was also utilized.
Inclusion and Exclusion Criteria
Population. Included were sample populations that were at least 16 years of age and older
with an acute a hip fracture. Studies were excluded if the sample included people younger than 16
years old, if subjects underwent an elective total hip arthroplasty or revision, subjects with midshaft or unspecified femoral fractures, and subjects that were deemed non-operable.
Intervention. The intervention is the administration of a single injection nerve block
(femoral [FNB], psoas compartment, fascia iliaca compartment [FICB], 3-in-1) prior to surgery for
a hip fracture as an adjunct to standard preoperative opioid analgesics. Both nerve stimulator,
landmark, and ultrasound guided (USG) forms of administration were included in order to capture
more robust evidence. Types of blocks (ropivacaine, bupivacaine, etc.) were included in the search
and not separately evaluated. Studies were excluded if the nerve block administration occurred
right before, during or after surgery, if a continuous nerve block catheter was placed, if the subject
also received an epidural or spinal anesthetic in conjunction with the nerve block, or if nerve block
administration occurred for a different injury.
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Comparison. The primary comparisons were those patients treated with just standard
administration of preoperative opioid analgesic/morphine equivalents for pain control. Studies
were excluded if the comparison was a non-steroidal anti-inflammatory medication,
acetaminophen, or epidural/spinal anesthesia.
Outcome. Primary outcomes consisted of acute pain management, frequency of opioid
pain medication use, and overall opioid medication use. Secondary outcomes included delirium,
opioid or nerve block adverse side effects, mortality, functional status, and length of stay. Studies
that failed to address at least one of these outcome measures were excluded.
Search Outcomes
The initial search using the aforementioned keywords yielded 62 articles across 4 databases
(see Appendix C). Papers were removed if they were duplicates, did not meet the inclusion criteria,
and did not meet content criteria. The final 10 papers evaluated adults who presented to the
hospital for a hip fracture (see Appendix D).
Intervention and Comparison Characteristics
Each review compared administration of a single injection nerve block (femoral [FNB],
psoas compartment, fascia iliaca compartment [FICB], 3-in-1) prior to surgery for a hip fracture
alone or as an adjunct to standard preoperative opioid analgesics. The most common medication of
comparison was with morphine (oral, intramuscular, or intravenous), followed by fentanyl and
alfentanil. Each study included either a nerve stimulator, landmark, or USG form of
administration, although the USG technique recently emerged as the gold standard (Scurrah et al.,
2018). Across studies, administration of preoperative nerve blocks included trained ER physicians,
orthopaedic surgeons, anesthesiologists, paramedics, and junior physicians.
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Measures
The ten studies/reviews focused primarily on the efficacy preoperative regional nerve
blocks. The Visual Analog Scale (VAS), Verbal Rating Scale (VRS) and the Numeric Rating Scale
(NRS) were the primary tools used to measure and report differences in pain. Changes in pain
scores on the VAS, VRS, or NRS was considered significant if P<0.05 at a 95% confidence
interval (CI). Another outcome measure included safety (10 studies/reviews), which was defined
as the frequency of adverse events stemming from either the intervention or comparison group.
The reviews also reported on the resultant reduction in opioid analgesic use (9 studies/reviews),
which was reported in milligrams. Finally, the 1 review reported on the time to the next opioid
analgesic dose following regional nerve block administration, which was recorded in minutes.
Results
Efficacy of Regional Nerve Blocks. The three systematic reviews demonstrated reductions
in preoperative hip fracture pain for the FNB, FICB and 3-in-1 nerve block (About-Setta et al.,
2011; Riddell et al., 2016; Ritcey et al., 2016). Two reviews concluded that the evidence supports
regional nerve blocks as an effective method in reducing pain compared to standard opioid care.
Only one single injection study did not favor regional block efficacy, but pre-block pain scores
were significantly higher in this group (Guay et al., 2017). The two combined systematic reviews
and meta-analyses found significant reductions in preoperative hip fracture pain associated
movement and positioning. However, acute pain was variable or not therapeutically different at
rest (Fadhlillah & Chan, 2017; Steenberg & Miller, 2018).
The integrative review evaluated the current care continuum in the ED for hip fracture
patients. The single randomized controlled trial deemed high quality evaluated preoperative FICB
to the control group: systemic morphine combined with a placebo injection mimicking an FICB.
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The study (n=48) found static, or resting, pain (P<0.01) and dynamic, or moving, pain (P=0.02)
relief superior in the FICB group compared to the morphine and placebo FICB group (Wennberg
et al., 2018). The narrative review evaluating eight randomized controlled trials found that regional
nerve blocks reduce hip fracture pain on movement within 30 min of block placement (Scurrah et
al., 2018). Additionally, FICB, FNB, psoas compartment, and combined nerve block provided
superior analgesia to placebo or ‘standard care’ in hip fractures (Scurrah et al., 2018).
In the AAOS (2014) review, five out of the six (n=593 patients) high strength studies
evaluated preoperative pain management. The sixth study investigated preoperative and
postoperative pain. VAS scores indicated significant reduction in reported preoperative pain in five
out of the six studies and nonsignificant reduction of pain in the other study (Mean preoperative
VAS score of placebo vs. FICB: 68.2 vs. 61.4, P=0.59) (AAOS, 2014).
The single randomized controlled trial (n=266) evaluated the effect of FNB and opioids
(n=129) to conventional opioid treatment (n=137) on preoperative pain (VAS) and preoperative
opioid consumption (Unneby et al., 2017). Self-rated and proxy VAS pain scores decreased from
baseline to 12 hours in intervention group versus the control (P<0.001 and P=0.003, respectively)
(Unneby et al., 2017).
Safety. The clinical practice guideline, the four systematic reviews, the randomized
controlled trial, and the integrative review found no major immediate complications, such as
adverse toxicity or persistent paresthesia, for FNB, FICB, or 3-in-1 blocks (AAOS, 2014; AboutSetta et al., 2011; Guay et al., 2017; Riddell et al., 2016; Ritcey et al., 2016; Unneby, 2017;
Wennberg et al., 2018).
The two combined systematic reviews and meta-analyses also evaluated safety of single
injection nerve blocks in preoperative hip fracture pain. In the review and analysis by Fadhlillah &
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Chan (2017), the FICB group had reduced analgesia breakthrough (n=57 vs. n=73), reduced
drowsiness/sedation (n=1 vs. n=22), reduced desaturation (n=0 vs. n=4), and reduced nausea and
vomiting (n=3 vs. n=7) compared to standard preoperative analgesia. Both groups reported
localized bruising (n=3), though (Fadhlillah & Chan, 2017). In the review and analysis by
Steenberg & Miller (2018), there was a 1.7% incidence rate of hematoma at the injection site.
The narrative review by Scurrah et al. (2018) found one study where the inpatient mortality
with the regional nerve block was 5.5% versus 15% (P=0.0024) in the standard care control group.
There was no statistically significant difference in cardiac complications, deep vein thrombosis,
pulmonary embolism, nausea and vomiting, respiratory infection, stroke, surgical wound infection,
or urinary tract infections with regional nerve blocks compared to standard preoperative hip
fracture pain management (Scurrah et al., 2018).
In terms of safety by administration, the narrative review also found that junior staff,
paramedics, and new residents can be trained to effectively administer nerve blocks without
increase in complications (Scurrah et al., 2018). The AAOS (2014) clinical practice guidelines for
hip fractures also reports that the type of administering provider (emergency physicians,
anesthesiologists, orthopaedic surgeons) did not compromise patient safety.
Reduction in opioid use. Three of the systematic reviews, the narrative review, and one of
the combined systematic review and meta-analysis found less opioid consumption in the
preoperative nerve block intervention group compared to the opioid control group (Abou-Setta et
al., 2011; Guay et al., 2017; Ritcey et al., 2016; Scurrah et al., 2018; Steenberg & Miller, 2018).
However, Ritcey et al. (2016) were unable to conclude whether reduced IV opiate use also resulted
in reduced adverse effects due to under-reporting in most of the studies.
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Unneby et al. (2017) found that the FNB and opioid intervention group received
significantly less opioids than the control group (Intravenous: 2.3 + 4 mg vs. 5.7 + 5.2 mg,
P<0.001; Oral: 2.1 + 4.1 mg vs. 3.6 + 6.4 mg, P=0.017). Additionally, patients with dementia in
the intervention group received less intravenous opioids compared to the control group (2.1 + 3.3
mg vs. 5.8 + 5 mg, P<0.001) (Unneby et al., 2017).
Delay in additional opioid use. Steenberg & Miller (2018) analyzed two studies
comparing the need for additional opioids in the FICB group versus the opioid control group in
preoperative hip fracture patients. In one study, the FICB group waited an average of 245 minutes
(95% CI: 2055, 285) before requesting another opioid dose compared to the opioid control group,
which waited an average of 145 minutes ((95% CI: 14.9, 275) (P=0.12)). The other study reported
similar findings for the FICB group, which waited an average of 516 minutes (95% CI: 437, 594)
compared to 270 minutes in the opioid control group ((95% CI: 189, 351) (P<0.01)). In total, the
FICB group waited longer for first request of additional analgesia compared to the opioid control
group (SMD= 0.93 (95% CI: 0.02,1.84) (P=0.05)) (Steenberg & Miller, 2018).
Discussion of Evidence to be Used for Project
A key theme in this review is that preoperative pain control for hip fractures can be
improved. Single injection nerve blocks as a solitary intervention or as an adjunct to opioids
compared to standard preoperative opioid care offer a promising solution to this problem.
Although four of the reviews each report that only one study has a low risk of reporting bias, all
ten studies included in this review conclude overall that single injection, regional nerve blocks are
at least as effective, if not superior, to standard opioid analgesia in reducing hip fracture pain.
About-Setta et al. (2011) concludes that there is a moderate level of evidence supporting
use of nerve blocks in hip fractures, but that more rigorous studies will help provide definitive
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guidelines. However, the AAOS (2014) clinical practice guidelines give a strong recommendation
for the use of preoperative regional analgesia. Additionally, all ten studies report that the use of
regional nerve blocks in hip fractures is relatively safe. However, the authors of each review cite
the underreporting of adverse events as an issue that should be more transparent in study results.
The other eight reviews provided evidence that supported the ability of single injection
regional nerve blocks in reducing additional preoperative opioid consumption. These results are
promising, given the substantial side effects associated with opioid consumption. One review
reported on the delay in time associated with additional opioid doses following administration of
the FICB compared to the opioid control groups (Steenberg & Miller, 2018). These two studies
were part of the meta-analyses, which conveys a high level of evidentiary support. Despite low
heterogeneity of the p-value, the authors caution readers to consider study heterogeneity.
Limitations
The review presents several limitations. In terms of the reviews, the small sample sizes,
heterogeneity of study methodology, and moderate to high reporting bias should all be considered
when weighing the evidence. Additionally, the overall evidence level supporting regional nerve
blocks in preoperative hip fracture pain is moderate. Limitations of the DNP student may include
search methods that could have eliminated pertinent articles.
Conclusion
Use of opioid analgesics remains a common practice in pre-operative hip fracture
management. However, the review demonstrates the efficacy and safety of single injection
regional nerve blocks in hip fracture patients. The overall evidence supporting nerve block use is
moderate due to small sample sizes and study design variation, but it offers an alternative to
current preoperative pain management practices and patient outcomes (see Appendix E).
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Phenomenon Conceptual Model
The phenomenon of preoperative pain management in hip fractures is best conveyed
through the revised Theory of Symptom Management Model (Dodd, Janson, & Facione, 2001).
Symptoms can be distressing to a patient and can pose management challenges for healthcare
providers. This theoretical model defines a symptom as a subjective experience that conveys
personal biopsychosocial changes. A sign, though is defined as an objective, or measurable
component of a disease (Dodd et al., 2001). Both signs and symptoms help inform the course of
patient care.
However, this model primarily focuses on effectively managing active patient symptoms,
which are based on patient perception and report. Consideration is also given to nonverbal patients
and patients who are at risk for developing symptoms. In the revised model, there are three
domains: the Person, Health and Illness, and the Environment (Dodd et al., 2001). The Person
domain pertains to intrinsic variables that impact the way in which a person perceives and
responds to the symptom experience. These include demographic, psychological, sociologic, and
physiologic variables (Dodd et al., 2001). The Health and Illness domain includes individual risk
factors, injuries, diseases, or disabilities. These variables also impact the symptom experience and
a person’s desire to seek care. Conversely, the absence of signs or symptoms does not necessarily
equate to health (Dodd et al., 2001). Finally, the Environmental domain represents an individual’s
environment encompasses physical, social, and cultural variables. The context in which symptoms
occur impact the symptom experience as well as the type of treatment and projected outcomes
(Dodd et al., 2001).
These three domains influence the three dimensions of the model: Symptom experience,
Management strategies, and Outcomes. A symptom experience is an individual’s perception,
assigned meaning, and response to a symptom (Dodd et al., 2001). The goal of symptom
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management is to delay or avoid a negative health outcome. Components of symptom management
include the time, method, amount, location, and purpose of an intervention designed to mitigate or
eliminate patient symptoms (Dodd et al., 2001). Finally, the Outcomes represent the product of
symptom experience and management. This dimension includes functional and emotional status,
self-care, quality of life, morbidity, mortality, and cost of interventions (Dodd et al., 2001).
Overall, this model offers a comprehensive conceptualization of symptom expression. It
helps clinicians understand symptoms in order to select appropriate management strategies and
assess the impact of such strategies (Dodd et al., 2001). Therefore, this model serves as the best
lens through which to view the phenomenon of preoperative hip fracture pain (see Appendix F).
Project Plan
Purpose of Project and Objectives
The orthopedic physicians at XXX decided to implement a standardized protocol where all
individuals admitted with a primary diagnosis of an isolated, operable hip fracture would receive a
localized, single injection nerve block. The protocol was enacted in March 2018 to safely and
effectively manage pain for this patient population from the point of emergency department
admission to the operating room. The purpose of this quality improvement is therefore to
determine whether or not the preoperative nerve block protocol addresses the following objectives:
reduced preoperative pain, reduced narcotic drug use, reduced narcotic-related adverse effects, and
reduced potential cost of inpatient care in this population.
Design for the Evidence-based Initiative
The nerve block protocol was designed by the orthopaedic CNS through the
communication of all of the key stakeholders involved in hip fracture care (see Appendix G). This
protocol and list of responsibilities is located in the education booklets in the ED and OU for staff
to reference. The CNS has already educated all care teams and units involved to familiarize
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employees with the protocol and associated expectations. Anesthesiology also maintains the
organization’s standard for educating the patient on the nerve block and clearing a patient for the
nerve block. Feedback was collected on an ongoing basis to identify, address, and mitigate factors
that may contribute to negative patient outcomes. For data analysis, the pre-block protocol data is
obtained through a retrospective record review based on the aforementioned outcome indicators.
Setting
The organization of interest is a local West Michigan hospital that sees a full spectrum of
patient conditions and provides a variety of services. The units involved in this proposed practice
change, though, include the emergency department (ED), the post-anesthesia care unit (PACU),
the surgical floor (OR), and the orthopaedic medical-surgical unit (OU). These units are integral to
the continuum of care for hip fracture patients from time of admission to discharge. Patients
admitted in the ED for hip fractures will typically go straight to preoperative holding on the
surgical floor if there is an opening in the OR schedule. If not, then the patients are sent to the OU
until there is an opening in the OR. After the procedure in the OR, the patients are held in PACU
to monitor for anesthesia side effects, vital signs, and pain. Once the patient is deemed stable, the
patient is transferred to the OU for postoperative care until discharge. In 2017, there were 168 hip
fractures, of which 146 received surgical correction.
Participants
All patients admitted to the organization for hip fractures and are eligible for surgery from
March 1, 2018 to December 31, 2018 were offered the nerve block as part of the established
protocol. The pre-nerve block group included all patients admitted to the organization for hip
fractures and underwent surgical correction from June 1, 2017 to February 28, 2018. Patients were
excluded if their hip fracture is non-operable, for nerve block refusal, or if there is a medical
allergy to the nerve block medication.
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Model Guiding Implementation
Utilization of Rosswurm & Larrabee’s Model for Evidence-Based Practice Change (1999)
provides the best approach to effectively evaluate this preoperative nerve block protocol for hip
fractures. This model provides a systematic process for implementing evidence-based change
through the assistance of key stakeholders and in the context of the cultural climate. It was initially
developed to correct the continued struggle of research utilization by practitioners (Rosswurm &
Larrabee, 1999). This model has six steps for implementation and sustainability (see Appendix H).
First step: Assess need for change in practice. This step involves the collection of data in
order to identify a clinical practice problem. This organizational data is then compared to external,
or national databases, from which care standards are established. Information is also gleaned from
key stakeholders to substantiate the practice problem’s effect on patient care (Rosswurm &
Larrabee, 1999).
Second step: Link problem with interventions and outcomes. The problem must then be
translated into a standardized nursing or clinical classification. This facilitates ease of data
collection, analysis, and dissemination. This step then includes connecting the practice problem to
interventions and subsequent outcome expectations (Rosswurm & Larrabee, 1999).
Third step: Synthesize best evidence. At this step, the proposed interventions and
outcomes are further clarified to facilitate a more specific literature review. Practitioners appraise
the quality of the literature and level of evidence. The purpose of this step is therefore to
investigate whether the current literature supports the need for the practice within that particular
healthcare context (Rosswurm & Larrabee, 1999).
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Fourth step: Design a change. Following the synthesis of evidence, practitioners may
then construct a protocol that details the sequence of steps for the practice change. Process and
outcome indicators will be outlined for recording and data analysis. These indicators outline staff
actions, resources, costs, and projected patient care outcomes (Rosswurm & Larrabee, 1999).
Fifth step: Implement and evaluate change. Implementation of the practice change must
be accompanied by continuous monitoring, reinforcement, and openness to staff feedback. Data is
collected for the length of the intervention trial and analyzed to verify whether the practice change
was successful in meeting the desired outcome indicators. Staff and peer feedback, cost, and
benefits and risks are also taken into consideration when evaluating the effectiveness of the change
(Rosswurm & Larrabee, 1999).
Sixth step: Integrate and maintain change. Following implementation of a pilot protocol,
staff and organizational buy-in help produce a revised protocol for approval. Integration and
sustainability of the practice change occurs when stakeholders are continuously informed and
included. This enhances the acceptance and perceived feasibility of the practice change within the
context of the organization (Rosswurm & Larrabee, 1999).
Implementation Steps and Strategies
Following the organizational assessment, SWOT analysis, and literature review, the goal of
the next steps is to assess whether or not this protocol is effective in meeting the specified
measures. In accordance with Rosswurm and Larrabee’s model (1999) and Powell et al. (2015)
implementation strategies, steps to evaluate this nerve block protocol include the following:
1. Build a coalition prior to implementation by November 5th, 2018.
According to Powell et al. (2015), building a coalition refers to recruiting and building
relationships with key stakeholders in order to partner in the implementation initiative.
Steps to build a coalition involves:
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Prior cultivated relationship in April 2018 with the designated orthopaedic CNS
that spearheaded this initiative. She serves as a liaison to the orthopeadic,
emergency medicine, internal medicine, and anesthesia providers, the nurse
practitioners, physician assistants, the rapid response team, unit managers (ED,
PACU, OR, and OU managers), and the ED, PACU, and OR clinical nurse
CNSs and CNLs. This was because the organization’s Institutional Review
Board (IRB) was not yet granted to the DNP student.

•

The DNP student established communication and attended meetings with the
othopaedic CNL, orthopaedic nurse navigator, the orthopaedic unit nurse
manager, the Clinical Service Director, and the trauma CNS throughout several
meetings in May, June, and July of 2018.

•

The DNP student met with Grand Valley State University Statistician graduate
student in May 2018 to review excel spreadsheet for data collection.

•

The DNP student established phone and email communication with the Clinical
Information Specialist, the information data specialist who helped facilitate data
extraction from the patient EHR for data analysis.

2. Submit application to Grand Valley and organization’s IRB for project approval and
EHR access by November 9th, 2018.
•

Submission of the IRB application by this data to both organizations granted
access to the EHR system for retrospective and real-time data collection.

•

Approval also ensured ethical oversight by the two organizations.

•

The organization already implemented the protocol in March 2018. The DNP
student’s role therefore involved data collection, analysis, and assistance with
possible recommendations protocol revision.
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3. Develop an evaluation blueprint by November 9th, 2018.
According to Powell et al. (2015), developing an evaluation blueprint includes “1) an
aim/purpose; 2) scope of the change; 3) timeframe and milestones; and 4) appropriate
performance/progress measures” (p. 8). Steps needed to formulate a blueprint for
evaluating the nerve block protocol include:
•

The aim/purpose or clinical question was stated earlier. The protocol was
already implemented in March 2018.

•

The scope of the change includes the units affected by the proposed nerve block
protocol. These include the ED, PACU, OR, and OU.

•

The timeframe and specific data measures will be explained in later sections.

4. Evaluation of workflow modifications pending approval of IRB access by November
26th, 2018. Steps include:
•

The orthopaedic CNS already compiled the appropriate order sets for hip
fracture admission, which includes the nerve block, due to the DNP student’s
initial inability to access charts and the EHR. This, combined with the hip
fracture care flowchart, facilitated ease of ordering and mitigate staff and
provider confusion.

•

Monthly audits (Point 5) will determine whether the protocol is being followed
by the staff involved in this protocol.

5. Perform weekly audits of the outcome measures starting December 1, 2018, pending
Grand Valley State University and the organization’s IRB approvals.
Powell et al. (2015) define audits as a process of collecting and summarizing clinical
data acquired over a designated time period. Providing clinicians and administrators with
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this data will facilitate real-time evaluation and monitoring of the protocol success in case
protocol revisions must be made. Steps include:
•

Meet with Clinical Information Specialist who will help direct the DNP student
on how to extract the data appropriate for the project. Meetings and/or phone
call correspondence occurred on the same day each month that the DNP Student
was present at the organization to perform the chart audits.

•

Monthly audits occurred from the time of IRB approval until Janurary 2018 in
order to collect a large enough sample size for comparison of the preprotocol/no nerve block patient sample. The IRB approval was requested until
January 2019 to ensure complete data retrieval.

•

Audits for the retrospective data of the pre-protocol/no nerve block patient
sample occurred within the same timeframe.

•

The monthly data will be analyzed and turned around to both the orthopaedic
CNS, the othopaedic CNL, the orthopaedic nurse navigator, the orthopaedic unit
nurse manager, the Clinical Service Director, and the trauma CNS for review.

6. Dissemination of final project report by March 25th, 2018.
Following data collection and analysis, the final strategy involves sharing local
knowledge with key stakeholders to inform them about how care quality has changed as a
result of protocol implementation (Powell et al., 2015). Sister organizations and other local
organizations may build on the success or general knowledge of this nerve block protocol
to promote care quality in their hip fracture patients.
•

Disseminating results to ED, PACU, OR, OU and other pertinent providers and
administrators via email or in person by March 25th, 2019.
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Measures
Measurement tools and indicators include electronic health record data on: (1)
Demographics of hip fracture patients (age, sex, race); (2) Hip fracture post-surgical readmission
rates to the ED within 30 and 90 days; (3) Hip fracture mortality rates in the hospital; (4) Preoperative and post-operative Numeric Pain Scale or Visual Analog pain scores; (5) Pre-block and
post-block Numeric Pain Scale scores; (6) Time from admission to the ED to administration of a
nerve block; (7) Time from admission to the ED to the OR (preoperative waiting time); (8) Time
from block administration to the OR; (9) Number of preoperative opioid analgesics used in
morphine milliequivalents (MME); (10) Number of postoperative opioid analgesics used in MME;
(11) Length of patient stay; (12) Cost of inpatient treatment and stay; (13) Incidence of pneumonia;
(14) Incidence of delirium; (15) Incidence of unexpected intensive-care unit transfer; (16) Whether
the nerve block was given/refused; and (16) Patient discharge destination.
Data Collection Procedures
In order to ensure the safety and privacy of participants and research data, patient names
and MRNs did not leave the premises of the organization’s computers. The DNP student was the
lead data collector. This collection was overseen by the orthopaedic CNS at the organization (see
Appendix J). The DNP student utilized REDCap software at the site to encrypt the data and ensure
patient privacy. Pertinent data was obtained with the assistance of the Clinical Information
Specialist and Trauma CNS. The only patient demographic data collected for entering into the
REDCap encrypted software included: patient age, sex, and race.
The other outcome indicators are numeric variables that did not risk identifying the patient.
For instance, each of the data outcomes were numerically coded and did not involve protected
health information (i.e. Sex: 0=Male, 1=Female; Race: 0=Caucasian, 1=African American,
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2=Hispanic, 3=Other; Hip fracture readmission: 0= no readmission in 30 days, 1=readmission in
30 days). Patient chart information did not leave the organization’s campus. Only the data relating
to the study outcomes were pulled, coded, and entered into REDCap prior to departure from the
organization. This ensured security of protected health information and eliminated the potential for
such information to be deliberately or unintentionally discovered. Data collection occurred weekly
at the organization and ended in February 2019.
Data Management
Collected data relevant to the patient outcome measures were stored in REDCap. The
original patient charts were kept within the organization’s EHR system and did not depart from the
campus databases. This data will be available to the organization for review and audit per the
designated 7 years after conclusion of this project. The REDCap data was exported to and
analyzed by a Grand Valley State University statistics graduate student.
Analysis
The procedure for analysis of the current state of hip fracture pain management included
recording of the aforementioned measurement indicators. In order to evaluate the preoperative
waiting time, a dataset of patient transfers was manually reviewed. The time in hours was then
quantified into a variable that could be processed into REDCap. Based on the quantified
preoperative times, each patient’s preoperative pain score was then manually extracted from the
data set. Once the delineation between preoperative and postoperative periods was outlined, the
length of stay, postoperative patient numeric pain score, and postoperative opioid analgesic use
were also calculated. The term “morphine milligram equivalents” (MME) accounts for differences
in opioid drug type and strength by equating its dose in milligrams of morphine (CDC, 2017).
MMEs were calculated using American Pain Society (2016) CDC (2016b) conversions (see
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Appendix I). Oral medications were converted to MME with the oral morphine conversion factor.
Intravenous (IV) medications were converted to MME with the IV morphine conversion factor.
The graduate statistics student transferred the de-identified data from the exported REDCap
file to the SAS statistical software for data analysis at Grand Valley State University. Outcome
evaluation underwent inferential statistic testing through independent samples t-test. Assuming that
the data fits a normal distribution, this method tested for significance between the two independent
patient groups (no nerve block vs. nerve block) and for organizational compliance with the
protocol. The outcome measures are displayed later as charts and graphs for presentation.
Resources & Budget
The financial justification for this project should be noted (see Appendix K). So far, the
calculated cost of in-kind mentoring of the organization’s CNS was forty hours, which totals
$1,920 (Salary.com, 2018a). In terms of the nerve block kits, there is one kit stocked on the
intensive care unit and three kits stocked in the ED. The items in each kit all could be used when a
nerve block is administered. The contents of each kit total $30.95. Extra emergency supplies
outside of the kit, but kept on the aforementioned units, include one bag of lipids ($9.12) and one
continuous nerve stimulator kit ($51.59). Four kits ($123.80) and the additional extra emergency
supplies ($242.84) would total $366.64.
The organization decided to use the ultrasound-guided (USG) technique for administration.
The USG technique has shortest time to onset of action, requires the least amount of local
anesthetic, and has fewer complications compared to the other administration methods (Bates,
Rhodes, & Amini, 2015).
Two common procedural (CPT) codes are needed for nerve block administration. The CPT
code 76942, which is for Ultrasonic guidance for needle placement, has a facility price in
Michigan of $32.50 (CMS, 2018a). The second CPT code 64447, which is for a single femoral
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nerve block injection, has a facility price in Michigan of $67.99 (CMS, 2018b). An
anesthesiologist earns approximately $176.00 per hour (Salary.com, 2018b). It would therefore
cost $44.00 for the fifteen minutes needed to administer the block. Narcotic cost savings would be
negligible, according to the organization’s Clinical Pharmacy Services Program Director and
Manager (see Appendix L).
The three DRGs used interchangeably for hip fractures have an estimated operating room
supply cost of $2500 per hip fracture case (XXX, 2018). The cost of the procedure itself will not
change, which varies from $18,294.49 to $38,640.43 for the Grand Rapids and Muskegon area
(Blue Cross Blue Shield, 2015). The projected cost for length of stay in a non-profit organization
in Michigan is $2,298.00 (Kaiser Family Foundation, 2018). The organization provided the cost of
$405.00 per day for an OU unit, and so these approximations were used for estimation.
Usual length of stay for hip fractures 50 years and older is approximately 5.6 days
(Basques, Bohl, Golinvaux, Leslie, Baumgaertner, & Grauer, 2015; Nikkel, Kates, Schreck,
Maceroli, Mahmood, & Elfar, 2015). However, the organization’s trauma CNS reports that the
average length of stay for their hip fracture patients was 3.89 days in 2017. This includes all hip
fractures, regardless of whether they had surgery.
Shortening the time from ED admission to surgery can reduce length of hospital stay (LOS)
by one full day (Basques et al., 2015). This protocol may result in LOS cost savings due to its
expedited pre-surgical pathway and the nerve block to mitigate pain and narcotic adverse
reactions. Reduction in LOS is calculated by adding the cost of one day of care with the
reimbursement for the nerve block procedure. For reduction in LOS of one day, hip fracture care
costs are reduced from $1,575.45 to $1,170.45. Using the 146 operable hip fractures in 2017, this
translates into a projected annual cost savings of $73,801.54.
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Timeline
Utilization of Rosswurm and Larrabee’s Utilization of Rosswurm & Larrabee’s Model for
Evidence-Based Practice Change (1999) provides the best approach to effectively implement a
preoperative nerve block protocol for hip fractures.
1. Assess need for change in practice. Meetings with key stakeholders began on April

25, 2018. The DNP student met with the aforementioned key stakeholders of the
organization between April and September 2018 to conduct an organizational
assessment and a SWOT analysis assess the factors that would positively or negatively
impact the nerve block protocol started in April 2018.
2. Link problem with interventions and outcomes. The problem of preoperative hip

fracture pain management was identified. The DNP student reviewed the literature for
the preoperative nerve block efficacy in hip fracture patients.
3. Synthesize best evidence. The review found that the local, single injection nerve

blocks as a means of reducing preoperative pain and opioid analgesic use was at least
moderately effective. Therefore, the previously enacted protocol was justified by
research.
4. Design an evaluation of the practice change. The DNP student created a plan for

evaluation and analysis of the data collected during this quality improvement project.
This included a data dictionary and collection tool in REDCap that reflects the outcome
measures of interest. This program de-identified sensitive patient information. Data
analysis occurred with the assistance of a Grand Valley State graduate statistics student.
5. Evaluate the practice change. Weekly audits started on January 7, 2018, following

Grand Valley State University and the organization’s IRB approvals. Data was
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collected for the length of the intervention trial and analyzed to verify whether the
practice change was successful in meeting the desired outcome indicators. Data
collection ended in February 2018. Staff and peer feedback, cost, and benefits and risks
were also taken into consideration at each weekly audit and during unit meetings in
order to evaluate the effectiveness of the change.
6. Integrate data that supports this change. Following the end of this quality

improvement project, staff and organizational buy-in will help with future protocol
revision and data analysis. The EHR order sets and standards of care for all hip fracture
surgical candidates admitted to the organization will also help sustain this practice
change.
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Project Result Overview
Approach Modifications

During the process of data medical record review, additional patient characteristics were
identified that were not delineated in the original project proposal. In the spirit of continuous
quality improvement, the project was modified to accommodate: a change in patient date ranges
for each collection group, inclusion and exclusion criteria for additional patient characteristics, and
additional data measures.
Per preference from the organization, the DNP student used the REDCap-encrypted
program instead of an Excel spreadsheet for data collection. The REDCap data dictionary was then
modified from the original data dictionary to reflect the aforementioned changes. The student met
with and developed this plan in collaboration with the site mentor and project advisor. These
modifications fell within the parameters of the original IRB approvals from the organization and
Grand Valley, as they just expanded upon the original outcomes outlined in the project proposal
(see Appendix M). The project was modified as follows:
Timeframe changes. Once the DNP student was granted access to the electronic charts, it
was discovered that there were a number of preoperative nerve blocks administered to patients
within the month of March. Additionally, due to the timeframe to submit the data for analysis, the
timeframe of evaluation was reduced from 9 months to 7 months for the pre-nerve block and nerve
block groups. Therefore, the timeframe for the pre-nerve block patients was shifted from the
original June 1, 2017 – February 28, 2018 to August 1, 2017 – February 28, 2018. The timeframe
for the nerve block group was then shifted from the original April 1, 2018 – December 31, 2018 to
March 1, 2018 – September 30, 2018. This resulted in 50 patients in each group.
Patient characteristics. Following initiation of medical record review, the extent of patient
variability also required further definition. While reviewing the electronic patient charts, there
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were several concerning patient diagnoses and medications that the DNP student and her advisors
felt were not representative of the organization’s usual hip fracture population. In order to preserve
the integrity and assumption of normality between the two groups, several exclusion criteria were
added during the electronic chart review process.
The original exclusion criteria included: non-operable patients, nerve block refusal, or a
medical allergy to the nerve block medication. Additional exclusion criteria added during
evaluation included: active cancer with chemotherapy and/or radiation treatment, diagnosis of
generalized chronic pain, diagnosis of low back pain with routine use of prescribed narcotics,
multi-trauma cases, current polysubstance abuse, and patients placed on comfort care while at the
organization. Patients were still included if they had a diagnosis of low back pain and no narcotic
use or used narcotics as needed per their medication list. Patients with cancer were also included if
there was no evidence of active chemotherapy and/or routine narcotic use in the electronic chart.
Data outcomes. While manually reviewing each chart, data outcome entries were
expanded to include: a diagnosis of dementia; incidences of post-surgical 60-day readmission
rates; pre and post-operative pain scores and reassessment scores for non-narcotic medications; pre
and post-operative pain scores and reassessment scores at 24, 48, 72, and 96 hours of LOS; and
pre-block and post-block pain reassessment scores. Additionally, separate labels for oral (PO) and
intravenous (IV) narcotic medication were created for each narcotic intake data measure in order to
more accurately report MME usage by patients. Pain scores and pain reassessment scores were
included for non-narcotic medications, such as acetaminophen and cyclobenzaprine, in order to
capture the full context of pain control. If there was no narcotic pain medication administered
within a set time frame, a value of 0 was entered into REDCap. Patient pain reassessments that
were marked as “sleeping” were not included in the reassessment score total and were assigned a
value. Organization compliance with the nerve block protocol was also added as an outcome.
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Project Results
Demographics. Following the application of the aforementioned timeframe changes and
patient exclusion factors, 50 patients in each group met inclusion criteria for a total sample of 100
patients (n=100). All 50 patients in the nerve block group received a nerve block in the
preoperative period. Patient demographics were checked for normality (see Appendix N). Males
(n=16; 32%) and females (n=34; 68%) were fairly evenly distributed across the pre-block patient.
In the nerve block group, similar findings were seen with males (n=13; 26%) and females (n=37;
74%). Additionally, the racial distribution of Caucasians (n=48; 96%), African Americans (n=1;
2%), and Hispanic (n=1; 2%) patients in the pre-block group was equal in distribution to the
Caucasians (n=48; 96%), African Americans (n=1; 2%), and Hispanic (n=1; 2%) patients in the
nerve block group. Patients admitted in either group with a pre-existing diagnosis of dementia
were also evenly split between the pre-block group (n=18; 36%) and the nerve block group (n=19;
38%). In terms of age, the pre-block group ranged from 57 to 99 years (M=80.54; SD=9.30). In the
nerve block group, age ranged from 60 to 100 years (M=82.80 years; SD=10.45).
Care service time periods. Timeframes for care service transitions were calculated using
REDCap (see Appendix O). The mean time in hours from patient admission to the OR in both
groups was 21.92 hours, but ranged from 3.60 hours to 68.37 hours (SD=10.05). The average time
in hours from patient admission to nerve block administration was 4.80 hours in the nerve block
group, but ranged from 0.78 hours to 24.95 hours (SD=4.69). Finally, the average time from nerve
block administration to the OR in the nerve block group was 17.29 hours, but ranged from 0.27
hours to 70.98 hours (SD=11.81).
Narcotic use. Narcotic use in oral and IV MME was calculated for total narcotics used
preoperatively, postoperatively, and at 24, 48, 72, and 96 hours of inpatient stay (see Appendix P,
Tables 1-6, Figures 1-4). Both PO and IV narcotic use in either group underwent non-parametric t-
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testing because normality assumptions were not met. The preoperative oral MME consumed in the
pre-block group ranged from 0.00 to 30.00 (M=5.80, SD=7.02). In the nerve block group, the oral
MME intake ranged from 0.00 to 47.50 (M=7.40, SD=10.77) (p=0.80). The preoperative IV MME
consumed in the pre-block group ranged from 0.00 to 36.70 (M=9.65, SD=8.41). In the nerve
block group, the intake of IV MME ranged from 0.00 to 30.00 (M=8.44, SD=8.14) (p=0.39).
The postoperative oral MME consumed in the pre-block group ranged from 0.00 to 142.50
(M=30.68, SD=32.97). In the nerve block group, the intake of MME or oral narcotics ranged from
0.00 to 95.00 (M=21.10, SD=22.13) (p=0.23). The postoperative IV MME consumed in the preblock group ranged from 0.00 to 28.00 (M=1.91, SD=4.57). In the nerve block group, the intake of
IV MME ranged from 0.00 to 16.00 (M=0.91, SD=2.84) (p=0.10).
At 24 hours of inpatient stay, the average amount of oral MME consumed in the pre-block
group (N=50) and the nerve block group (N=50) was 7.45 and 6.80, respectively (p=0.27). At 48
hours of inpatient stay, the average amount of oral MME consumed in the pre-block group (N=49)
and the nerve block group (N=48) was 13.77 and 9.27, respectively (p=0.42). At 72 hours of
inpatient stay, the average amount of oral MME consumed in the pre-block group (N=36) and the
nerve block group (N=34) was 12.85 and 7.94, respectively (p=0.33). At 96 hours of inpatient stay,
the average amount of oral MME consumed in the pre-block group (N=14) and the nerve block
group (N=17) was 10.27 and 7.20, respectively (p=0.98).
At 24 hours of inpatient stay, the average amount of IV MME consumed in the pre-block
group (N=50) and nerve block group (N=50) were 10.51 and 8.48, respectively (p=0.19). At 48
hours of inpatient stay, the average amount of IV MME consumed in the pre-block group (N=49)
and nerve block group (N=48) were 1.35 and 0.63, respectively (p=0.11). At 72 hours of inpatient
stay, the average amount of IV MME consumed in the pre-block group (N=36) and nerve block
group (N=34) were 0.09 and 0.29, respectively (p=0.28). Finally, at 96 hours of inpatient stay, the
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average amount of IV MME consumed in the pre-block group (N=14) and nerve block group
(N=17) were 0.00 and 0.20, respectively (p=0.41).
Data on the difference between narcotic use before and after nerve block administration
could not be analyzed due variance in time periods from admission to block and block to the OR.
Since the times varied so much among the nerve block group patients, there was unlikely to have
reoccurring doses.
Pain levels. Pain levels, or ratings, were averaged and entered into REDCap. Data analysis
compared pain levels over designated time periods via non-parametric t-tests. For the pre-nerve
block group, the average preoperative pain was 6.22/10 (SD=2.54) with an average reassessment
level of 4.25/10 (SD=2.31). For the nerve block group, the average preoperative pain was 5.95/10
(SD=2.00) with an average reassessment level of 4.52/10 (SD=2.44). During the postoperative
period until discharge, the pre-nerve block group averaged a 4.37/10 (SD=1.83) with an average
reassessment level of 2.88/10 (SD=1.92). In the nerve block group, the average pain level during
the same time period was 3.78/10 (SD=1.71) with an average reassessment level of 2.45/10
(SD=1.77). Therefore, both of the pre and postoperative comparisons were not significant (see
Appendix Q, Figure 1).
Pain levels and pain reassessment levels were also averaged, entered into REDCap, and
analyzed at 24, 48, 72, and 96 hours after surgery in both groups. During the first 24 hours after
surgery, the average pain level in the pre-block group was 4.75/10 (SD=1.89) with an average
reassessment level of 3.36/10 (SD=2.08). For the nerve block group, the average pain level was
4.11/10 (SD=1.75) and average reassessment level was 2.69/10 (SD=2.03) during the same time
period. This does not represent a statistically significant change.
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The average pain level 48 hours after surgery in the pre-block group was 4.27/10
(SD=2.08), with an average reassessment level of 2.84/10 (SD=2.13). During the same timeframe,
the nerve block group average pain level was 3.57/10 (SD=2.03) and average reassessment level
was 2.21/10 (SD=1.97). At 72 hours after surgery, the average pain level of the pre-block group
was 3.71/10 (SD=2.08) and the average pain reassessment level was 2.37/10 (SD=2.18). For the
nerve block group, the average pain was 3.67/10 (SD=2.11) and average pain reassessment was
2.64/10 (SD=2.22). Finally, 96 hours after surgery saw the pre-block group with an average pain
level of 3.99/10 (SD=1.85) and reassessment of 2.88/10 (SD=1.92). For the nerve block group, the
average pain level was 3.51/10 (SD=2.60), with an average reassessment pain level of 2.35/10
(SD=2.24). These do not represent statistically significant changes (see Appendix Q, Figure 2).
The efficacy of the nerve block on preoperative pain levels was calculated using a paired ttest comparing the difference in the average pain level before nerve block administration and the
average pain level after nerve block administration (see Appendix Q, Figure 3). There was a
statistically significant average reduction of 2.20/10 (SD=1.96) for patients (p<0.0001).
Length of stay. Overall, the intervention did not have a clinically significant effect on
length of stay (see Appendix R). The duration of patient stay for the pre-block group ranged from
1.91 days to 27.75 days, with an average of 4.61 days (SD=4.13). The duration of stay in the nerve
block group ranged from 1.64 to 27.44 days, with an average of 4.34 days (SD=3.63) (p=0.90).
This represents a reduction in length of stay by 6.51 hours, or 27% of the 24-hour day.
Cost savings. The nerve block group saw a reduction in length of stay by 6.51 hours. The
projected cost of patient stay, including the cost of the procedure and an anesthesia consult, totals
$2,279.69 at 4.61 days. However, the adjusted care cost for patient stay, including reimbursement
reductions and new costs from a 6.51 hour stay reduction, totals $1,883.55. This results in a
$57,836.44 annual cost savings for the organization as a result of the nerve block protocol.
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Secondary outcomes. Secondary outcomes included incidence of pneumonia, incidence of
delirium, unplanned transfer to the intensive care unit, readmissions, location of discharge, and
mortality. Incidences of pneumonia did not differ between the two groups, with 1 patient in each
group having a diagnosis of pneumonia upon discharge. There was also only 1 unplanned transfer
to the intensive care unit in the nerve block group, but this transfer was unrelated to the nerve
block. In terms of delirium, the nerve block did produce a reduction in episodes of delirium, but it
was not statistically significant (p=0.10). The nerve block also did not reduce the incidence of
delirium in patients with diagnosis of dementia present on admission (see Appendix S, Table 1).
There were 4 readmissions each in the pre-block and nerve block groups. In the pre-block
group, one 30-day and one 90-day readmission were related to the hip fractures, while the other
two were pertained to another medical problem. In the nerve block group, there was one 90-day
readmission related to the patient falling on the surgically corrected hip again. The other
readmissions were related to other comorbidities. The majority of the patients were discharged to
subacute rehabilitation, followed by discharge to home with home health and to the home with
outpatient physical therapy (see Appendix S, Table 2). There was one death in the nerve block
group, but this was unrelated to the block. It was sudden so the patient was not placed on hospice.
Organization compliance. There were 112 total patients admitted to the organization with
a hip fracture during the 7 month period of the initial nerve block protocol administration.
Although only 50 patients met inclusion criteria for the nerve block group, 72 out of the 112
patients received a nerve block within the preoperative period. Organization compliance with the
protocol was therefore 64% for the first 7 months of protocol implementation. After reviewing the
trauma registry data that was available from October 1, 2018 to December 31, 2018, there were 41
hip fracture patients, of which 30 received preoperative nerve blocks. Compliance therefore
increased to 73% in the 3 months following the timeframe for the DNP student evaluation.
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Overall, the data indicates that there are no statistically significant reductions in oral and IV
narcotic use for total narcotics used preoperatively, postoperatively, and at 24, 48, 72, and 96 hours
of inpatient stay. There was also no statistically significant reduction in patient length of stay or
patient adverse effects, such as incidence of pneumonia, delirium, and unplanned transfer to the
intensive care unit. Patient pain levels and reassessment levels between both groups were often
comparable as well. The only statistically significant finding was the preoperative reduction in
pain levels following nerve block administration. Due to variance in time of preoperative block
administration, narcotic difference could not be calculated and the correlation between reduction in
pain level and narcotic use could not be determined.
Although there were no statistically significant values, there were some clinically
significant reductions in pre and postoperative intravenous narcotic use, postoperative oral narcotic
use, and episodes of delirium. However, the data still does not indicate that there is a direct
association between administration of the nerve block and the anticipated outcomes. Possible
reasons for differences between the anticipated and observed results includes sample size,
compliance rate, and variance in time of preoperative nerve block administration. Stricter control
over these factors may lead to outcomes consistent with current literature. However, the literature
does not define the most effective time to administer a preoperative nerve block. This could be an
organization-specific intervention that requires future research. Overall, these changes could
produce more effective, safer pain control and increased cost savings for the organization.
Strengths of this project include the detailed electronic chart review completed by the DNP
student to compile fifty data measures for collection on each patient. However, due to the quality
improvement and retrospective nature of this project, the DNP student was unable to influence the
processes that impacted this data.
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Limitations

The factors that limit internal validity of this project are the small sample size of the patient
population, the lack of time standardization for nerve block administration, and the current
organization compliance with the protocol. Due to the retrospective and non-research nature of this
project, such factors could not be controlled by the DNP student during evaluation. Additionally,
no multiplicity adjustments were used for data outcomes. Future efforts to minimize limitations
should center around sampling a larger homogenous population, as several results were trending
towards significance with this project’s current sample size. Future efforts should also focus on
greater organization compliance to the nerve block protocol to minimize variance between care
transition times and nerve block administration.
Conclusion
Hip fractures are a debilitating injury that typically requires surgery. One of the most
important aspects of hip fracture management is pain control, especially in the preoperative period.
Current standards of practice primarily reflect an opioid model of analgesia, but these medications
are associated with dangerous adverse effects. Recent literature highlights the success of local,
single injection nerve blocks to aid in preoperative pain management. In accordance with the
literature, the orthopaedic physicians at the organization implemented a preoperative, single
injection nerve block protocol for hip fracture patients in March of 2018. However, this protocol
had not yet been evaluated for organization compliance and patient outcomes.
This quality improvement project investigated whether this protocol reduces hip fracture
pain, use of systemic opioid analgesics, decreases incidence of adverse opioid effects, and reduces
cost of care. Results were not statistically significant in reducing oral and intravenous narcotic use
before (p=0.80; p=0.39) and after (p=0.23; p=0.10) surgical correction, nor was there statistically
significant change in adverse effects (p=0.10) and length of stay (p=0.90) despite a 6.51 hour stay
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reduction between groups. However, these results could be deemed clinically significant due to the
implications of these reductions on patient care outcomes. A larger sample size could also produce
more significant results. Protocol compliance was 66% over seven months. However, there was a
statistically significant reduction in average preoperative pain levels following administration of
the nerve block (p<0.0001).
The results of this project were consistent with the literature; nerve block injection may
reduce preoperative pain for patients with an operable hip fracture. Further investigation is needed
to determine if narcotic use and length of stay could be impacted if time variability in nerve block
administration were reduced and if protocol compliance were increased.
Implications for Practice and Further Study in the Field
This DNP project encourages multiple practice implications. The literature supports the
efficacy of single injection nerve blocks for hip fracture patients in the preoperative period.
Although the results of the data outcome evaluation were not statistically significant, they are
clinically significant. This presents an ongoing opportunity for the organization to improve upon
protocol compliance and block administration standardization. A larger sample size could also be
more beneficial in obtaining significant results. Currently there is no assigned individual tracking
such outcomes, nor is there a designated process to ensure time standardization of preoperative
block administration. Appointing an employee to continue monitoring patient data measures and
organization compliance will provide expedited feedback turnaround.
Revising the current protocol to include a time standardized administration of the nerve
block may also help reduce the administration variability. Only a few articles in the literature
review accounted for time from admission to block placement. The randomized control trial by
Unneby et al. (2017) administered femoral nerve blocks within 82.9 minutes (+/- 95.7 minutes) of
admission.
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Another study by Haslam et al. (2013) evaluated timing of USG femoral nerve blocks in
hip fracture patients when administered by ED physicians and residents. Although there were no
direct time measures in their results, their block timing included administration immediately after
X-ray confirmation of fracture, or immediately after medical assessment and triage. This highlights
the need for improved timing of block administration upon admission to the ED, with possible
future focus on training ED physicians, residents, NPs, and PAs to administer a USG nerve block.
These changes could streamline processes and expedite pain control. The protocol may then
produce the patient outcomes that originally led to the protocol introduction.
Sustainability Plan
Continued stakeholder commitment, funding, and resource provision will help ensure that
this nerve block protocol is sustainable. Although there are several internal weaknesses and
external threats that may complicate protocol compliance, the organization’s internal strengths and
opportunities may overcome these barriers. Data tracking sustainability beyond this quality
improvement project may be successful if a key person is appointed to continue tracking cost and
quality outcome measures. Additionally, unit feedback and cooperation may allow for more
accurate and timelier EHR input if workload demands are balanced with patient care.
Dissemination of Results
Dissemination of project results will first occur at the university in front of the DNP student
project faculty and site advisor on March 25, 2019. The dissemination of results to the organization
is pending, but will occur before April 27, 2019. The final draft of the scholarly quality
improvement project with be uploaded to ScholarWorks© following final approval from the DNP
student’s faculty advisor. Additionally, the DNP student could disseminate findings in the form of
a literature publication in order to further current knowledge about preoperative, single injection
nerve blocks in hip fracture patients.
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Reflection on DNP Essentials

The American Association of Colleges of Nursing’s (AACN, 2006) eight essential DNP
competencies helped guide the DNP student through this quality improvement project and towards
graduation. These competencies serve as a foundation for DNP practice, and were developed and
met during the evaluation of the organization’s nerve block protocol.
Scientific Underpinnings for Practice
Scientific underpinnings for practice reflect the rigor of the doctoral education and the basis
for nursing actions (AACN, 2006). The scientific basis of this quality improvement was rooted in
the comprehensive literature review that validated the organization’s implementation and current
use of the nerve block protocol. The patient data outcomes were also derived from the scientific
literature. Additionally, evidence-based nursing theory and implementation models, such as the
Model for Evidence-Based Practice Change (Rosswurm & Larrabee, 1999) guided the DNP
student’s evaluation of the protocol in order to offer recommendations for improvement.
Organizational and Systems Leadership
In order to affect change in organizational and policy arenas, the DNP student must be
proficient in leading quality improvement and change sustainability (AACN, 2006). The DNP
student demonstrated organizational and systems leadership by first conducting an organizational
assessment of current practice needs (Burke & Litwin, 1992). This assessment validated the need
for improved preoperative pain control in hip fractures. The DNP student therefore formulated a
quality improvement project that evaluated current organization practices. The DNP student also
demonstrated leadership through continuous, independent communication and inquiry with key
stakeholders at the organization. Sensitivity to the organization’s culture and populations,
including patients and providers, were also maintained during the project (AACN, 2006).
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Clinical Scholarship and Analytical Methods
Scholarly nursing practice is a hallmark of DNP education (AACN, 2006). The DNP is
equipped to translate evidence into practice at the patient-provider interface in order to produce
improved health care outcomes (AACN, 2006). During this quality improvement project, the DNP
student used a systematic, analytic approach to appraise current literature on the use of nerve
blocks in hip fracture patients. The DNP student then designed a quality improvement project to
evaluate the organization’s current practice. Utilization of technology and the assistance of a
statistical consultant allowed the DNP student to successfully examine the effect of the
organization’s current nerve block protocol and offer suggestions for improvement.
Information Systems Technology
Use of information technology allows the DNP to assess, manage, and apply new
knowledge related to quality improvement initiatives (AACN, 2006). The DNP student utilized the
Cerner electronic health record system for manual chart review. The encrypted REDCap software
was used to ensure privacy of patient data collection. Finally, the use the SAS software for data
analysis allowed the DNP student to interpret the efficacy of the nerve block protocol. Legal and
ethical issues were avoided through the approval of the organization’s and university’s IRBs.
Advocacy for Health Care Policy
Addressing current care issues through policy development promotes increased access and
quality of care, especially for those who consistently experience health care disparities (AACN,
2006). This DNP project focused on hip fracture patients, who are typically considered a
vulnerable population due to their age and comorbidities. The DNP student collaborated with key
stakeholders to critically analyze and offer recommendations for the current preoperative nerve
block protocol for this population. This project did not include policy change and the state, federal,
or international level.
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Interprofessional Collaboration
Interprofessional collaboration requires effective communication, partnering, and
leadership in order to contribute to healthcare advancement (AACN, 2006). The DNP student
worked collaboratively with physicians, a pharmacist, organization leadership, unit nurses an
ancillary staff CNSs, CNLs, a statistician, and faculty advisors to develop and implement this
quality improvement project. This collaboration allowed the DNP student to complete and
disseminate the evaluation results of the current preoperative nerve block protocol in hip fractures.
Clinical Prevention Population Health
Health promotion and disease prevention is a foundational principle of DNP clinical
practice (AACN, 2006). This project focused on reduction of preoperative pain, reduction of
narcotic use, reduction in adverse effects, and reduction in length of patient stay, which results in
faster restoration of mobility. The student collected and evaluated data measures specific to hip
fracture patients in order to provide recommendations for improved pain management in this
population. The psychosocial and cultural components of care related to clinical prevention were
included through application of the Theory of Symptom Management Model (Dodd et al., 2001).
Advanced Nursing Practice
Advanced nursing practice includes advanced assessment and holistic treatment throughout
a variety of care settings. These clinical experiences also help the DNP graduate comprehend the
consequences of care decisions (AACN, 2006). For this quality improvement project, the DNP
student created and sustained therapeutic partnerships with key organizational stakeholders in
order to facilitate evaluation of the organization’s nerve block protocol. Additionally, the DNP
student demonstrated advanced clinical judgment, systems thinking, and accountability through the
development, evaluation, and dissemination of the current operational state and impact of the
protocol.
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Appendix A
The Burke-Litwin Model of Organizational Performance and Change

Figure 1. A model of organizational performance and change. Reprinted from “A Causal Model of
Organizational Performance and Change,” by W. W. Burke and G. H. Litwin, 1992, Journal of
Management, 18, 528. Copyright 1992 by Southern Management Association.
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Appendix B
SWOT Analysis of the ED, PACU, OR, and OU
Strengths

Weaknesses

•

Lean Six Sigma trained leadership

•

Culture of process improvement

communication and pain management

•

Organization-wide teamwork

for hip fractures

•

Magnet designation

•

TJC orthopaedic certifications

•

Hospital Quality Awards

•

Clinical Quality Awards for joint
replacement

•

Nurse navigator

•

Joint classes

•

•

Providers meeting face to face

•

Staffing issues with anesthesiology,
PACU, OU, RR

•

New provider unfamiliarity

•

Transitions of care

•

DRG codes

Opportunities
•

Decrease use of opioids in midst of

Lack of standardized protocol for

Threats
•

Other local hospitals already

current opioid crisis

implemented nerve block protocol for

•

New evidence supporting nerve blocks

hip fractures

•

Established protocols for hip fractures

•

More competitive local branding

from sister hospitals of parent

•

Insurance company preference

company

•

Centers for Medicaid and Medicare

•

Orthopaedic group merger

reimbursement measures
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Appendix C
Search Terms Used for Literature Review in Databases
Database
Keywords

PubMed
MeSH: Hip fractures,
preoperative period,
nerve block, pain
management

Keyword
Hip fractures AND
Combinations Preoperative period
AND nerve block

CINAHL
Nerve block, hip
fracture,
preoperative
pain
management
Hip fracture
AND nerve
block

Hip fractures AND
Preoperative period
AND Nerve block
AND Pain
management
Search
Results

4 articles

14 articles

Cochrane
Preoperative,
nerve block, hip
fracture, pain
management
Preoperative
AND nerve
block AND hip
fracture
Nerve block
AND hip
fracture AND
Pain
management
1 article

Web of Science
Nerve block, hip
fracture,
preoperative,
pain
management
Preoperative
AND nerve
block AND hip
fracture AND
pain
management
“hip fractures”
“nerve block”
43 articles
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Appendix D
PRISMA Flow Diagram of Systematic Search
Records identified through
database searching
(n = 62)

Records after duplicates removed
(n = 50)

Records screened
(n = 50)

Records excluded
(n = 23)

Full-text articles assessed
for eligibility
(n = 27)

Full-text articles excluded,
with reasons
(n = 17)

Studies included in
quantitative synthesis
(meta-analysis)
(n =10)

Figure 1. Flow diagram of search selection process. Adapted from “Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement,” by D. Moher, A. Liberati, J.
Tetzlaff, D. Altman, and PRISMA Group. Copyright 2009 by PLoS Medicine.
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Author (Year)
Purpose
AAOS (2014)
Compile a
practice
guideline based
on current
evidence to
inform care of
hip fractures in
patients over
age 65

Design (N)
Systematic
review of
prospective
randomized
clinical trial
studies (N=6
studies) on
regional
analgesia for
preoperative
pain control

Table of evidence on the efficacy of nerve blocks
Inclusion
Intervention vs
Results
Criteria
Comparison
Full article
Comparison of
Efficacy:
report of
preoperative
• Five out of the six (n=593 patients)
clinical study
administration of
high strength studies were limited
starting from
local anesthetic
to preoperative pain, sixth study
1966; peerin fascia iliaca or
included preoperative and
reviewed; 10
femoral
postoperative
or more patient compartment on
• VAS scores indicated significant
per group;
pain control vs.
reduction in reported preoperative
English; >50% control group as
pain in 5/6 studies and
patient follow- measured by
nonsignificant reduction of pain in
up in studies
VAS.
one study (Mean preop VAS score
with follow-up
of placebo vs. FICB: 68.2 vs. 61.4,
time points;
P=0.59)
Mean age of
Safety of Intervention:
65 with hip
• Type of administering provider
fracture
(emergency physicians,
anesthesiologists, orthopaedic
surgeons) did not compromise
patient safety
• FICB
o Hematoma, no adverse toxicity,
no persistent paresthesia,
decreased delirium
• 3-in-1 nerve block
o No difference from control in
pulse, oxygenation, or
respiratory rate during study
• FNB

Conclusion
Studies to date
show reduced hip
fracture
preoperative pain.
AAOS (2014)
strength of
recommendation is
strong (4 stars) for
use of preoperative
regional analgesia
in the form of
nerve blocks.
Further research
needed on
following
outcomes needed:
total opioid use
pre-op, delirium
incidence, and
length of stay.
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Abou-Setta
(2011)
Review
benefits and
harms of
pharmacologic
and nonpharmacologic
hip fracture
pain
management

Systematic
review
(N=83
studies – 64
RCTs, 5 nonRCTs, 14
cohort
studies);
Nerve block
(N=29
RCTs)

RCTs, nonRCTs, cohort
studies, and
case-control
studies; No
language
restrictions;
January 1990December
2010; Adults >
50 y.o. with
hip fracture;
any pain
management
intervention;
No specifics on
pain method or
point of time in
care
(preoperative,
intraoperative,
postoperative)

Nerve block (3in-1, combined
lumbosacral
plexus, FICB,
femoral, lumbar
plexus +sciatic
nerve, epidural
and combined
blocks)
compared with
placebo,
standard care, or
another nerve
block.

• No local, systemic complications
Efficacy:
• 5 of 29 RCTs evaluated
preoperative pain for nerve block
vs. opioid analgesic control.
• FICB
o One study (n=48) found
static (P<0.01) and dynamic
(P=0.02) pain relief superior
in FICB group compared to
morphine + placebo FICB.
Less mean total IM
morphine consumption (0
mg vs. 6 mg, P<0.01) with
FICB
• 3-in-1 preoperative nerve block
o One study (n=40) VAS score
2.0* at 20 minutes after
block. VAS score 2.1* at 2
minutes after control.
(*p<0.001 vs. VAS score
before FIC block or IV
alfentanil). VAS score at
positioning for spinal
anesthesia lower compared
to VAS of control (P=0.001)
o One study (n=94) Time to
best response/mean
difference faster in block
group (95% CI: -2.93 hours
[-5.48 to -0.38 h]) and
required less morphine per
hour than control (95% CI: -

Systematic review
not specific for
nerve blocks, but
one pain
management
method included in
review. Pooled
results for acute
pain in nerve block
studies were not
reported due to
significant
heterogeneity.
Moderate evidence
to suggest efficacy
of nerve blocks in
reducing pain in
hip fractures, as all
nerve block types
provided superior
analgesia to no
block or standard
care.
USG nerve block
provided most
significant effects
of regional block.
However, not
enough well
designed studies to
be completely
definitive.
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•

Fadhlillah
(2017)
Determine the
analgesic

Systematic
review and
metaanalysis

RCT in
English;
Patients
>18y.o. with

Single injection
pre-operative
FICB vs.
standard

0.68 mg/h [-1.23 to -0.12
mg/h])

FNB
o One study (n=50) Pain with
FNB less than control at 15
min (P<0.05) and 2 hours
(P<0.01)
o One study (n=14) Pain with
FNB less than control at 1
hour (p<0.04), but not
statistically significant at 4
and 24 hours
Safety of Intervention:
• FICB
o No adverse toxicity, no
hematoma, no persistent
paresthesia
o Greater sedation in the
morphine group (n=6) versus
the FICB group (n=1) at 180
minutes after block
administration (P=0.05)
• 3-in-1 nerve block
o No difference from control in
pulse, oxygenation, or
respiratory rate during study
• FNB
o No local or systemic
complications
Efficacy:
• Acute pain significantly reduced
with positioning and movement in

FICB is superior in
acute hip fracture
pre-operative pain
compared to
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efficacy and
(N=8 studies,
safety profile
645 patients)
of fascia iliaca
compartment
block (FICB)
on preoperative
pain in hip
fracture
patients

isolated
traumatic hip
fracture;
Received
single injection
FICB
preoperatively;
No search date
restriction
applied

preoperative
systematic
analgesia

Guay (2017)
Nerve block
efficacy as
preoperative or
postoperative
analgesia, or
supplemental
to general
anesthesia in
hip fractures

RCTs
comparing use
of nerve blocks
preoperatively,
operatively, or
postoperatively
to no regional
blockade
added to
general or
neuraxial
anesthesia as
part of care
provided for
adults > 16 y.o.
with hip
fracture/proxi
mal femoral

Participants
randomized to
peripheral nerve
block (FNB,
FICB, psoas
compartment)
using landmark,
nerve stimulator
or USG
technique added
to or not to
general or
neuraxial
anesthesia for
surgery vs.
opioids

Systematic
review (N= 7
trials, 322
participants)

FICB (SMD) = -1.82 (95% CI: 2.26 to -1.38, p<0.00001)
• Acute pain was variable at rest with
FICB (p=0.20)
Safety of Intervention:
• Reduced analgesia breakthrough
(n=57 vs. n=73)
• Reduced drowsiness/sedation (n=1
vs. n=22)
• Reduced desaturation (n=0 vs. n=4)
• Reduced nausea and vomiting (n=3
vs. n=7)
• Both groups reported localized
bruising (n=3)
Efficacy:
• Five studies evaluating single
injection nerve blocks (n=123)
compared to opioid analgesia
(n=122) showed decrease in opioid
consumption favoring nerve
blocks. SMD -0.73 (95% CI: -1.01,
-0.44)
• Out of three studies evaluating pain
at rest 30 minutes after single block
injection placement, two studies
demonstrated reduction in pain
favoring block. SMD -1.39 (95%
CI: -2.11, -0.66) and SMD-1.36
(95% CI: -2.04, -0.68),
respectively.
• Only one single injection study did
not favor regional block efficacy,

standard analgesia,
especially during
positioning and
mobilization. FICB
also is superior in
safety and reduces
reliance on
systemic
analgesics.
However, only one
study found low
risk of bias.

Regional blockade
reduces pain on
movement within
30 minutes after
block placement
and reduces opioid
consumption.
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fracture; From
1966 to 2016

Riddell (2016)
Update
evidence from
review by
Abou-Setta
(2011) on the
use of FNBs in
the ED for
managing hip
fracture pain in
the elderly.

Systematic
review (N=7
studies)

RCTs
published
between
December
2010 to May
2014 to serve
as an update to
Abou-Setta
(2011); AboutSetta (2011)
reference list
also used;
Use of femoral
nerve block in
ED settings
(pre-op) to
treat hip
fractures;
>65 y.o.;
pain and
analgesic
consumption

but pre-block pain scores were
significantly higher in this group.
Safety of Intervention:
• No trials reported major
complications
• More data needed to determine
impact on mortality
Femoral nerve
Efficacy:
block vs. placebo
• Four studies evaluated single
control (opioid
femoral nerve block injections:
or ‘standard
o FNB
care’ analgesic)
§ 1 study (n=50) Pain
with FNB less than
control at 15 min
(P<0.05) and 2 hours
(P<0.01)
§ 1 study (n=14) Pain
with FNB less than
control at 1 hour
(p<0.04), but not
statistically significant
at 4 and 24 hours
o 3-in-1 block
§ 1 study (n=94) Time to
best response/mean
difference faster in
block group (95% CI: 2.93 hours [-5.48 to 0.38 h]) and required
less morphine per hour
than control (95% CI: 0.68 mg/h [-1.23 to -

FNBs appear to be
effective in
managing acute
pre-operative hip
fracture pain in the
elderly. Metaanalysis could not
be conducted due
to study
heterogeneity.
Heterogeneity
encountered in
procedure type of
femoral block
placement and
methods used to
assess pain (VAS
vs. NRS). Only 1
study did not have
a high risk of bias.
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Ritcey (2016)
Investigate if
pre-operative
nerve blocks
result in
reductions in
pain, parenteral
opiate use, and
complications

Systematic
review of
RCTs (N=9
studies);
Metaanalysis
could not be
conducted

RCTs from
1946 to 2014;
> 16 y.o. with
acute hip or
femoral neck
fracture;
Single
injection FNB,

Single injection
nerve blocks
(Single injection
FNB, 3-in-1
FNB, or FICB)
with standard
pain
management

0.12 mg/h])
§ 1 study (n=36) showed
significant reduction in
NRS scores 4 hours
post-block (P<0.001)
and greater overall pain
relief measured by
summed pain intensity
difference of 11.0
(IQR=4.0 to 21.8) in
block + morphine group
vs. 4.0 (IQR=-2.0 to
5.8) in sham
injection/placebo +
morphine group
(P=0.001).
Safety of Intervention:
• 3-in-1 block
o No difference in adverse events
between groups in 1 study
(n=36)
• FNB
o No local or systemic
complications
Efficacy:
• Two studies utilized FNB (n=40),
Four studies utilized 3-in-1 FNB
(n=97), and three studies used
FICB (n=147)
• One study used ultrasound
guidance (USG), Five used
landmark technique, and three
studies used nerve stimulator

Regional nerve
blocks are at least
as effective and
potentially superior
in reducing pain
compared to
standard pain
management.

63
compared to
standard pain
management in
hip fractures

due to study 3-in-1 FNB, or
heterogeneity FICB;
Pre-operative
injection;
Pain score
reduction
recorded

Scurrah (2018)
Examine
current pain
management
for hip
fractures in the

Narrative
review of
RCTs (N=8)

Level 1 and
Level 2
Clinical trials,
clinical audits,
review articles,
and meta-

•

One study was double-blinded and
USG (n=36) found:
o Reduced 11-point numerical
rating scale (NRS) scores at 4
hours (p<0.001).
o Median summed pain intensity
difference (SPID) was 11.0
(IQR = 4.0 to 21.8) in FNB
group vs. 4.0 (IQR = -2.0 to
5.8) in placebo group over 4
hours
o Patients in placebo group
received more IV morphine
than FNB group (5.0 mg,
IQR= 2.0 to 8.4 mg vs. 0.0
mg, IQR= 0.0 to1.5 mg)
Safety of Intervention:
• None of the studies reported any
immediate complications
• One double-blinded USG study
found no difference in adverse
events between groups
• Unable to conclude whether
reduced IV opiate use also resulted
in reduced adverse effects due to
under-reporting in most of the
studies
Regional nerve
Efficacy:
blocks for acute
• Regional nerve blocks reduce hip
hip fracture pain
fracture pain on movement within
vs. standard care,
30 min of block placement (Guay,
opioid placebo
2017)

Sample sizes were
small in all RCTs,
ranging from 33154 participants.
Lack of doubleblinding in six out
of nine studies
resulted in
moderate to high
risk of bias. Only
one study had
overall low risk of
bias.

Nerve blocks
reduce acute pain,
opiate consumption
and delirium.
Nerve blocks for
hip fractures

64
elderly,
especially role
of regional
nerve blocks

analyses in
English; >18
y.o.; From
2007-May
2017

•

FICB, FNB, psoas compartment,
and combined nerve block
provided superior analgesia to
placebo or ‘standard care’ in hip
fractures (About-Setta, 2017)
• Preoperative single injection
regional nerve blocks reduce
consumption of opioids in hip
fractures and opioid side effects
o One study (n=48) found
less mean total IM
morphine consumption (0
mg vs. 6 mg, P<0.01) with
FICB versus morphine +
FICB placebo
o One study (n=161) found
33-40% reduction in
parenteral morphine
equivalent consumption and
reduction in opioid side
effects (3% vs. 12.4%,
P=0.03)
o FICB in one study (n=69)
reduced mean opioid use
from 6.2 mg to 2.0 mg
(P=0.01) and opioid
overdose incidence (7.2%
to 0%, P=0.001)
Safety:
• One study in inpatient mortality
with nerve block: 5.5% vs. 15%
(P=0.0024)

should be
integrated into
routine pain
management
protocols.
Additional research
is needed on cost
savings of nerve
blocks on length of
stay, mortality,
morbidity, and
quality of life.
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•

Steenberg
(2018)
Investigate
FICB benefit
and adverse
events in pre-

Systematic
review and
metaanalyses of
RCTs (N=8)
and quasi-

RCTs and
quasi-RCTs
from database
inception to
2016;

Comparison
FICB with nonintervention,
placebo,
paracetamol,
NSAIDs, opioid,

No statistically significant
difference in cardiac complications,
deep vein thrombosis, pulmonary
embolism, nausea and vomiting,
respiratory infection, stroke,
surgical wound infection, or
urinary tract infection (Abou-Setta,
2011)
• In FICB study (n=48), greater
sedation in the morphine group
(n=6) versus the FICB group (n=1)
at 180 minutes after block
administration (P=0.05)
• USG technique improves safety
and efficacy of nerve blocks
o One study found greater
sensory loss in medial thigh
with USG vs. “two-pop/loss
of resistance” technique”
(95% vs. 60%) and complete
sensory loss in anterior,
medial, and lateral thigh
(82% vs. 47%)
• Junior staff, paramedics, and new
residents can be trained to
effectively administer nerve blocks
without increase in complications
Efficacy:
• Two studies demonstrated
analgesic effect in FICB group in
first 30 minutes (P=0.001 fentanyl
control, P=0.047 morphine sulfate
control). Only one study had 3 hour

FICB has superior
analgesic effect
compared with
opioids during
movement, but not
at rest. FICB had
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operative hip
fracture
patients

RCTs (N=3)
(N=11 total)

> 18 y.o. with
hip fracture;
Pre-operative
administration;
Studies
published in
peer-reviewed
journals

or other nerve
blockades using
visual analog
scale (VAS) and
NRS;
Continuous
catheter and
single injection
included but
clearly
delineated;
Four (N=4)
studies included
opioids as
control

•

•

•

•

measurement, which was in favor
of FICB (P=0.01)
During movement, three studies
were in favor of FICB in first 30
minutes (P=0.02), SMD 1.58 (95%
CI: -2.90, -0.25). No difference at
rest (P=0.15), SMD -0.59 (95% CI:
-1.40,0.21)
Three studies reported mean dose
of additional morphine for:
o 4.11 mg (95% CI: 2.61,5.61)
vs. 7.42 mg (95% CI:
5.24,9.60) (P=0.03)
o 0 mg (95% CI: 0,0) vs. 6 mg
(95% CI: 5.38,6.62) (P<0.01)
o 0 mg (95% CI: -1.24,1.24) vs.
5 mg (95% CI: 2.20,7.80),
(P=0.03)
Meta-analysis of two studies on
request for additional opioids:
o 245 min (95% CI: 2055,285)
vs. 145 min (95% CI: 14.9,
275) (P=0.12)
o 516 min (95% CI: 437,594)
vs. 270 min (95% CI:
189,351) (P<0.01)
o Total between studies: longer
time for first request of
additional analgesia in FICB
group SMD 0.93 (95% CI:
0.02,1.84) (P=0.05)
Meta-analysis of four studies:

lower pre-operative
additional opioid
use and longer
duration between
block and first
analgesic dose.
N=3 RCTs were
rated with low risk
of bias and N=5
RCTs had a high
risk of bias. N=3
quasi-RCTs also
had a high risk of
bias. Concern with
heterogeneity of
studies and underreporting of
adverse effects.
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Unneby (2017) RCT (n=266
Determine
patients)
whether
preoperative
femoral nerve
block
administration
reduced acute
pain and opioid
use in elderly
patients,
including those
with dementia

Patients >70
years admitted
to orthopaedic
hospital ward
for hip fracture
prior to
surgery; With
or without
dementia;
Consent to
treatment

FNB + opioids
(n=129) or
conventional
opioid treatment
(n=137) effect
on preoperative
pain (VAS) and
preoperative
opioid
consumption

o FICB had lower preoperative
opioid analgesia SMD -1.89
(95% CI: -3.63, -0.14)
(P=0.03)
• Compared to opioids at rest, the
meta-analysis did not demonstrate
a difference.
Safety of Intervention:
• Incidence rate of hematomas at
injection site: 1.7% for articles
included in the review
• Eight cohort and retrospective
studies (n=2179) in full text of the
review cite 4 instances of
anesthetic toxicity (risk of 0.18%)
and 2 hematomas at the injection
site (risk of 0.9%).
Efficacy:
• Self-rated and proxy VAS pain
scores decreased from baseline to 12
hours in intervention group vs.
control (P<0.001 and P=0.003,
respectively)
• Intervention group received
significantly less opioids than
control group (IV, 2.3 + 4 mg vs.
5.7 + 5.2 mg, P<0.001; Oral, 2.1 +
4.1 mg vs. 3.6 + 6.4 mg, P=0.017)
• Patients with dementia in
intervention group received less IV
opioids compared to control group
(2.1 + 3.3 mg vs. 5.8 + 5 mg,
P<0.001)

Before
randomization,
n=191 patients
received opioids
(IV or oral) in the
ambulance or in the
ED, which may
account for lower
VAS pain scores.
However, FNB
further reduced
scores at 12 hours.
Recommend nerve
block
administration
performed in ED to
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Safety:
• No adverse events reported for
FNB
Wennberg
(2018)
Evaluate
current
evidence
surrounding
emergency care
for patients
admitted with
hip fracture,
with focus of
pain

Integrative
review
(N=38
articles: 34
quantitative,
4 qualitative)

Double-blind
RCTs to
qualitative
studies;
Publish from
1998 to 2017;
Described
chain of
emergency
care for hip
fractures after
falling; Age
range not
specified in
methodology

Regional nerve
Efficacy:
block vs.
• Of 34 quantitative studies, only
parenteral
three rated as High quality,
opioids,
however one study evaluated
Multifactorial
single vs. continuous nerve block
program impact
and one study evaluated nerve
on delirium,
blocks vs. NSAIDs. This left one
Experiences of
RCT that evaluated preoperative
physical pain,
FICB compared to systemic
current practices
morphine:
of managing
o The study (n=48) found
pain in hip
static (P<0.01) and dynamic
fractures,
(P=0.02) pain relief superior
Efficacy of fastin FICB group compared to
track
morphine + placebo FICB
management
using 5 point Verbal ranking
system, TENS
scale. Less mean total IM
efficacy,
morphine consumption (0
Describe lived
mg vs. 6 mg, P<0.01) with
experiences of
FICB
older adult in ED Safety:
• FICB
o No adverse toxicity, no
persistent paresthesia
o Greater sedation in the
morphine group (n=6) vs. the
FICB group (n=1) at 180
minutes after block
administration (P=0.05)

improve results of
this study.

After evaluating
the quantitative and
qualitative
evidence, the
results indicate that
nerve blocks can be
effective in
preoperative pain
management for
hip fractures.
However, the paper
presents with a
majority of lowlevel evidence
according to the
GRADE criteria.
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Appendix F
Theory of Symptom Management Model

Adapted from “Advancing the science of symptom management,” by M. Dodd, S. Janson, N.
Facione, J. Faucett, E.S. Froelicher, J. Humphreys … D. Taylor. Copyright 2001 by Journal of
Advanced Nursing.

70

FINAL DEFENSE
Appendix G

\.

FINAL DEFENSE

Figure 1. Adapted from “Hip fracture pathway,” by L. Zuckerman. Copyright 2017 by XXX.
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Figure 2. Adapted from “Staff educational powerpoint: Fascia iliaca blocks and local anesthetics
systemic toxicity (LAST),” by K.L. Johnson, A. Zeerip, and S. Veurink-Balicki. Copyright 2018
by XXX.
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Appendix H

Adapted from “A model for change to evidence-based practice,” by M.A. Rosswurm and J.H.
Larrabee. Copyright 1999 by Journal of Nursing Scholarship.
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Appendix I
Morphine Equivalent Conversions
Medication
HYDROmorphone
(Dilaudid)
Fentanyl
Oxycodone
AcetaminophenHYDROcodone
(Norco)
Tramadol (Ultram)

Route of
Administration
Intravenous

Morphine
Equivalent
0.15 mg

Conversion Factor

Intravenous
Oral
Oral

10 mcg
2 mg
1 mg

0.1
1.5
1

Oral

10 mg

0.1

6.7
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Appendix J
Letter of Agreement for Organization Advisor
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Appendix K
Budget and Projected Cost
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Appendix L
Cost of preoperative and postoperative narcotic medications included in order sets
Medication

Tramadol (Ultram)
AcetaminophenHYDROcodone
(Norco)
AcetaminophenOxyCODONE
(Oxycodone)

Dose, Route,
Frequency
50 mg, Oral, q 4
hours
5 mg/325 mg, Oral,
q 4 hours
5 mg, Oral, q 4 hours

Pain Level
Indication
Numeric
Scale
Moderate
(4-6/10)
Moderate
(4-6/10)

Morphine

1 mg, Intravenous,
q 2 hours

Moderate (46/10) –
Severe
(7-10/10)
Severe
(7-10/10)

HYDROmorphone
(Dilaudid)

0.5 mg, Intravenous,
q 4 hours

Severe
(7-10/10)

Cost

$0.60/tab
$0.17/tab

$0.18/tab

$1.63/syringe (syringe
manufactured as 4 mg/1mL
syringe, but charge would be
the same for any dose up to 4
mg)
$1.80/syringe (syringe
manufactured as 1 mg/mL
syringe, but charge would be
the same for any dose up to 1
mg)
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Appendix M
Institutional Review Board Approval

Figure 1. Institutional Review Board approval letter from the organization site.

FINAL DEFENSE

Figure 2. Institutional Review Board approval letter from Grand Valley State University.
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Appendix N
Patient Demographics
Pre-Block Group

Nerve Block Group

N=50

N=50

Male

N=16

N=13

Female

N=34

N=37

Caucasian

N=48

N=48

African American

N=1

N=1

Hispanic

N=1

N=1

Dementia Diagnoses

N=18

N=19

Average Patient Age

80.54 years

82.80 years

Sample Size
Gender Distribution

Race Distribution
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Table 1. Care transition timeframes output using SAS MEANS output procedure.
Care Service Timeframes in Hours
Calculated Field

N

Mean

SD

Minimum

Maximum

Time
Admission to OR Time

100

21.92

10.05

3.60

68.37

Pre-Block

50

21.98

9.08

3.72

56.32

Nerve Block

50

21.87

11.03

3.60

68.37

Admission to Block Time

50

4.80

4.69

0.78

24.95

Block to OR Time

50

17.29

11.81

0.27

70.98

Care Service Timeframe in Hours
80
70
60
50
40
30
20
10
0
Admission to OR

Admission to Block
Minimum

Mean

Block to OR
Maximum

Figure 1. Care transition timeframes illustrated as a graphical output.
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Table 1. Preoperative oral MME patient intake
Preoperative Oral MME

Pre-Block
Group
Nerve Block
Group

N

Mean MME

SD

Minimum

Maximum

50

5.80

7.02

0.00

30.00

50

7.40

10.77

0.00

47.50

p=0.80
Note. Data analysis with Wilcoxen Two-Sample Test (Z=2489.50).
50

narcpo_preop

40

30

20

10

0
0

1

group

Figure 1. Preoperative oral MME intake. Box plots depicting entire data set for the Pre-block
and Nerve Block groups. Group 0 refers to the Pre-block group, and group 1 refers to the Nerve
Block group.
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Table 2. Preoperative intravenous MME patient intake
Preoperative Intravenous MME

Pre-Block
Group
Nerve Block
Group

N

Mean MME

SD

Minimum

Maximum

50

9.65

8.41

0.00

36.70

50

8.44

8.14

0.00

30.00

p=0.39
Note. Data analysis with Wilcoxen Two-Sample Test (Z=2649.50).

narciv_preop

30

20

10

0
0

1

group

Figure 2. Preoperative IV MME intake. Box plots depicting entire data set for the Pre-block and
Nerve Block groups. Group 0 refers to the Pre-block group, and group 1 refers to the Nerve
Block group.
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Table 3. Postoperative oral MME patient intake
Postoperative Oral MME

Pre-Block
Group
Nerve Block
Group

N

Mean MME

SD

Minimum

Maximum

50

30.68

32.97

0.00

142.50

50

21.10

22.13

0.00

95.00

p=0.23
Note. Data analysis with Wilcoxen Two-Sample Test (Z=2697.50).
150

125

narcpo_postop

100

75

50

25

0
0

1

group

Figure 3. Postoperative oral MME intake. Box plots depicting entire data set for the Pre-block
and Nerve Block groups. Group 0 refers to the Pre-block group, and group 1 refers to the Nerve
Block group.
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Table 4. Postoperative intravenous MME patient intake
Postoperative Intravenous MME

Pre-Block
Group
Nerve Block
Group

N

Mean MME

SD

Minimum

Maximum

50

1.91

4.57

0.00

28.00

50

0.91

2.84

0.00

16.00

p=0.10
Note. Data analysis with Wilcoxen Two-Sample Test (Z=2703.50).

25

narciv_postop

20

15

10

5

0
0

1

group

Figure 4. Postoperative IV MME intake. Box plots depicting entire data set for the Pre-block and
Nerve Block groups. Group 0 refers to the Pre-block group, and group 1 refers to the Nerve
Block group.

86

FINAL DEFENSE
Table 5. Oral MME intake at 24, 48, 72, and 96 hours of inpatient stay
Total Oral MME Intake
N

Mean MME

Pre-Block Group

50

7.45

Nerve Block Group

50

6.80

24 Hours

p-value

0.27

48 Hours
Pre-Block Group

49

13.77

Nerve Block Group

48

9.27

p-value

0.42

72 Hours
Pre-Block Group

36

12.85

Nerve Block Group

34

7.94

p-value

0.33

96 Hours
Pre-Block Group

14

10.27

Nerve Block Group

17

7.20

p-value

0.98

Note. Outcomes for the Pre-block and Nerve Block groups analyzed through Wilcoxen TwoSample Test.
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Table 6. Intravenous MME intake at 24, 48, 72, and 96 hours of inpatient stay
Total Intravenous MME Intake
N

Mean MME

Pre-Block Group

50

10.50

Nerve Block Group

50

8.48

24 Hours

p-value

0.19

48 Hours
Pre-Block Group

49

1.35

Nerve Block Group

48

0.63

p-value

0.11

72 Hours
Pre-Block Group

36

0.09

Nerve Block Group

34

0.29

p-value

0.28

96 Hours
Pre-Block Group

14

0.00

Nerve Block Group

17

0.20

p-value

0.41

Note. Outcomes for the Pre-block and Nerve Block groups analyzed through Wilcoxen TwoSample Test.
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Change in Total Preoperative and
Postoperative Pain Levels and
Reassessment Levels
6.22

5.95

4.25

4.52

4.37

3.78

2.88

2.45

PREOPERATIVE PAIN PREOPERATIVE PAIN POSTOPERATIVE PAIN POSTOPERATIVE PAIN
REASSESSMENT
REASSESSMENT
Pre-Block Group

Nerve Block Group

Figure 1. The change in total preoperative and postoperative pain levels and reassessment levels.

Change in Pain Levels and Reassessment
Levels at 24, 48, 72, and 96 Hours Postoperation
4.75
4.11

3.36
2.69

4.27
3.57

2.84
2.21

3.713.67

2.372.64

3.993.51

1.912.35

PAIN 24 PAIN RE24 PAIN 48 PAIN RE48 PAIN 72 PAIN RE72 PAIN 96 PAIN RE96
HOURS
HOURS
HOURS
HOURS
HOURS
HOURS
HOURS
HOURS
Pre-Block Group

Nerve Block Group

Figure 2. The change in pain levels and pain reassessment levels at 24, 48, 72, and 96 hours
postoperatively and until discharge.
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Change in Pain Levels Following Nerve
Block Administration
7.55
5.002

PAIN PRE-BLOCK

PAIN POST-BLOCK

Figure 3. The change in reported pain levels following preoperative nerve block administration.
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Analysis of Variance for Length of Patient Stay
Classified by Variable Group
Group

N

Mean LOS (Hours)

Pre-Block

50

110.74333

Nerve Block

50

104.237667

Wilcoxen Two-

2544.0000

Sample Statistic
p-value

0.90
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Table 1. Secondary Patient outcome indicators.
Secondary Patient Outcomes

Pre-Block

N Total

Delirium

Pneumonia

ICU Transfer

50

11

1

0

50

5

1

1

Group
Nerve Block
Group

FINAL DEFENSE
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Table 2. Discharge location for patients across both groups.

Note. “Pre” group represents the pre-block group; “Post” represents the nerve block group; “sar”
represents subacute rehabilitation; “Other” is any discharge location.

Figure 1. Discharge location as exhibited in a chart representation.

